Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil in children after bidirectional cavopulmonary connection
NCT04054115Phase 1Terminated
- Sponsor
- SickKids
- Start
- Jul 2019
- Primary completion
- Feb 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Alprostadil Liposomes for Injection in congenital heart disease (CHD), sponsored by SickKids. Primary endpoint: Cerebral blood flow. Started Jul 2019; status: terminated.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT04054115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054115.